100 related articles for article (PubMed ID: 18337090)
21. Evolution of 17-β-estradiol, estrone and estrone-sulfate concentrations in late pregnancy of different breeds of mares using Liquid Chromatography and Mass Spectrometry.
Ledeck J; Dufour P; Evrard É; Le Goff C; Peeters S; Brutinel F; Egyptien S; Deleuze S; Cavalier É; Ponthier J
Theriogenology; 2022 Sep; 189():86-91. PubMed ID: 35738034
[TBL] [Abstract][Full Text] [Related]
22. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
23. Interrelationships of serum estradiol, estrone, and estrone sulfate, adiposity, biochemical bone markers, and leptin in post-menopausal women.
Castracane VD; Kraemer GR; Ogden BW; Kraemer RR
Maturitas; 2006 Jan; 53(2):217-25. PubMed ID: 15913927
[TBL] [Abstract][Full Text] [Related]
24. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
25. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
26. Reduced conversion of dehydroepiandrosterone into estrogens in premenarchal girls.
Bulletti C; Jasonni VM; Naldi S; Cristiani P; Flamigni C
J Endocrinol Invest; 1986 Oct; 9(5):375-81. PubMed ID: 2947948
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
[TBL] [Abstract][Full Text] [Related]
28. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
29. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
30. Androgen-oestrogen imbalance in men with chronic alcoholism and fatty liver.
Myking O; Aakvaag A; Digranes O
Alcohol Alcohol; 1987; 22(1):7-15. PubMed ID: 3593486
[TBL] [Abstract][Full Text] [Related]
31. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
32. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer.
Grosman H; Fabre B; Mesch V; Lopez MA; Schreier L; Mazza O; Berg G
Aging Male; 2010 Jun; 13(2):87-92. PubMed ID: 19921964
[TBL] [Abstract][Full Text] [Related]
33. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
Semjonow A; Hamm M; Rathert P
Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557
[TBL] [Abstract][Full Text] [Related]
34. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
35. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
36. Estrone sulfate, estrone and estradiol concentrations in normal and cirrhotic postmenopausal women.
Jasonni VM; Bulletti C; Bolelli GF; Franceschetti F; Bonavia M; Ciotti P; Flamigni C
Steroids; 1983 May; 41(5):569-73. PubMed ID: 6318400
[TBL] [Abstract][Full Text] [Related]
37. Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer.
Cabral PH; Iwamoto MW; Fanni VS; Barros Lda R; Cardoso SN; Mello LF; Glina S
Int Braz J Urol; 2013; 39(2):173-81. PubMed ID: 23683664
[TBL] [Abstract][Full Text] [Related]
38. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
[TBL] [Abstract][Full Text] [Related]
40. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
